Second Sight Medical Products Inc (EYES) Director Gregg Williams Purchases 15,875 Shares

Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams purchased 15,875 shares of Second Sight Medical Products stock in a transaction that occurred on Friday, October 5th. The shares were bought at an average price of $1.72 per share, with a total value of $27,305.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Gregg Williams also recently made the following trade(s):

  • On Wednesday, October 3rd, Gregg Williams purchased 24,075 shares of Second Sight Medical Products stock. The shares were bought at an average price of $1.79 per share, with a total value of $43,094.25.
  • On Friday, September 28th, Gregg Williams bought 9,223 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.90 per share, with a total value of $17,523.70.
  • On Monday, October 1st, Gregg Williams bought 25,098 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.88 per share, with a total value of $47,184.24.
  • On Wednesday, September 26th, Gregg Williams bought 10,878 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.96 per share, with a total value of $21,320.88.
  • On Monday, September 24th, Gregg Williams bought 15,520 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.86 per share, with a total value of $28,867.20.
  • On Friday, September 21st, Gregg Williams bought 15,875 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.80 per share, with a total value of $28,575.00.
  • On Wednesday, September 19th, Gregg Williams bought 29,616 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.82 per share, with a total value of $53,901.12.
  • On Monday, September 17th, Gregg Williams bought 15,875 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.79 per share, with a total value of $28,416.25.
  • On Thursday, September 13th, Gregg Williams bought 31,750 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.65 per share, with a total value of $52,387.50.
  • On Tuesday, September 11th, Gregg Williams bought 26,483 shares of Second Sight Medical Products stock. The shares were acquired at an average price of $1.68 per share, with a total value of $44,491.44.

Shares of EYES stock traded up $0.03 during trading hours on Tuesday, reaching $1.63. The stock had a trading volume of 18,351 shares, compared to its average volume of 394,820. Second Sight Medical Products Inc has a 12 month low of $1.05 and a 12 month high of $2.58. The firm has a market capitalization of $127.44 million, a P/E ratio of -2.76 and a beta of 3.07.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Tuesday, August 7th. The medical device company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Second Sight Medical Products had a negative net margin of 418.82% and a negative return on equity of 432.45%. The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.21 million. Analysts anticipate that Second Sight Medical Products Inc will post -0.58 EPS for the current fiscal year.

A number of equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. HC Wainwright set a $5.00 price objective on shares of Second Sight Medical Products and gave the company a “buy” rating in a research report on Wednesday, August 8th.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Featured Article: What are the risks of holding treasury bonds?

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply